bosentan anhydrous has been researched along with Substance Withdrawal Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frost, AE; Suleman, N | 1 |
| Behrends, M; Beiderlinden, M; Peters, J | 1 |
2 other study(ies) available for bosentan anhydrous and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Substance Withdrawal Syndrome; Sulfonamides; Treatment Outcome | 2004 |
Combination of sildenafil and bosentan for nitric oxide withdrawal.
Topics: Antihypertensive Agents; Bosentan; Extracorporeal Membrane Oxygenation; Female; Humans; Middle Aged; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Respiratory Distress Syndrome; Sildenafil Citrate; Substance Withdrawal Syndrome; Sulfonamides; Sulfones; Vasodilator Agents; Ventilator Weaning | 2005 |